SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending following its announcement of a record date for a digital token initiative, drawing significant community discussion around its venture into crypto. This attention is amplified by escalating geopolitical rhetoric, including commentary on Greenland and new tariff threats, which is heavily influencing market sentiment and broader economic concerns. The stock continues to be a focal point for politically charged narratives, with both enthusiastic supporters and market participants expressing strong, polarized views.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending due to regulatory clarity for ANKTIVA's resubmission for papillary bladder cancer, requiring no new clinical trials, coupled with expanding international approvals. The community is actively discussing the potential for a significant short squeeze, driven by high short interest and exceptional volume, as many investors embrace the long-term "cancer cure" narrative. This optimism persists even as the broader market faces headwinds, highlighting IBRX's standout performance and promising pipeline.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community closely follows its ongoing interactions with the FDA regarding the Biologics License Application for its Duchenne muscular dystrophy treatment, deramiocel, and the forthcoming submission of the full HOPE-3 clinical study report. Sentiment is divided, with many expressing strong bullishness and anticipating significant upside potential, while others voice concerns over perceived delays and discuss potential market manipulation, as analysts reiterate positive ratings for the company.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a significant non-exclusive licensing deal with Pfizer for its Matrix-M adjuvant, a move widely seen as powerful validation for the platform technology beyond its initial COVID application. The community is actively debating whether this partnership signals NVAX's evolution into a royalty-generating company and if high short interest will trigger a substantial upward move, despite some expressing frustration over the immediate market reaction amidst a broader downturn.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group Holding Ltd. is currently trending due to news of a strategic acquisition and a recent public offering that sparked extreme volatility. The community is sharply divided between anticipating massive upside driven by its low float and projected profitability, and expressing caution over its significant price swings. Traders are actively debating if this presents a compelling buying opportunity or a cautionary tale, drawing parallels to other high-momentum low-float stocks.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to highly positive Phase 1 clinical trial results for its drug, soquelitinib, in treating moderate to severe atopic dermatitis. This early data, especially in patients resistant to other treatments, is fueling community excitement about its potential as a significant new option in a large market, with discussions also revolving around the possibility of strategic partnerships or a buyout, alongside concerns about the drug's early development stage.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending following its acquisition of Texas Critical Data Centers and a new partnership to co-develop a large-scale AI data center campus in West Texas. The community is actively discussing an anticipated hyperscaler tenant announcement, which many believe could significantly boost the stock. Despite some lingering concerns over past allegations, investors are keenly focused on the company's strategic advancements in the high-demand AI infrastructure sector.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending as the community eagerly discusses its strategic expansion plans, including a new rare earth facility in France backed by government support, alongside advancements at its Stillwater magnet plant. These developments are viewed within the broader context of increasing geopolitical tensions and a global push for rare earth independence from traditional suppliers, though some express frustration over consistent price resistance and perceived manipulation compared to sector peers.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing an unprecedented surge driven by escalating AI demand for memory chips, leading to a global supply shortage. This momentum is reinforced by significant capacity expansion initiatives, including a Taiwan fab acquisition and a New York megafab groundbreaking, alongside notable insider buying and analyst upgrades. While many celebrate its "monster" rally and market-leading strength, a segment of the community remains cautious, labeling it an "overextended" "bubble stock" due for a pullback.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is a major talking point as geopolitical tensions escalate over the US's pursuit of Greenland and potential tariffs, prompting a Danish pension fund to divest from US Treasuries citing credit risk concerns. The community remains sharply divided, with some fearing broader international divestment and higher yields while others anticipate eventual rate cuts amid a slowing economy and increased Fed intervention.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio...

Instil Bio Pulls Plug On Lead Drug Development

Instil Bio stock falls after the company ends development of its lead cancer drug and exits a licensing deal, raising new questions about its pipeline and next steps.read more...

Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know 

Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet

Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice

Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results

Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?

Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade

<a href="https://stocktwits.com/symbol/TIL">Instil Bio’s stock</a> surged over 25% on Tuesday to levels last seen in early December after Jefferies upgraded the&nbsp;shares to ‘Buy’ from ‘Hold,’ with a new price target of $52 — more than double its current level.&nbsp;The upgrade reflects Jefferies’ confidence in the potential of Instil’s lead asset, SYN-2510, a novel PD-L1xVEGF bispecific antibody targeting multiple solid tumor cancers.Jefferies highlighted SYN-2510 as an “early mover” in the competitive cancer drug space, with significant upside expected from its planned clinical trials.&nbsp;A U.S. Phase 1b/2 study in non-small cell lung cancer (NSCLC) is scheduled to begin in the second half of 2025, focusing on driver gene mutation-negative non-squamous and squamous NSCLC patients.&nbsp;This trial will explore SYN-2510 in combination with chemotherapy, a promising strategy in frontline treatment settings.SYN-2510 is part of a global registrational strategy with China’s ImmuneOnco Biopharmaceuticals.&nbsp;In late 2024, ImmuneOnco started a Phase 1b/2 chemo combination study in China for frontline NSCLC. The collaboration aims to generate clinical proof-of-concept data in multiple solid tumors, with updates anticipated in early 2025.&nbsp;If successful, both companies may initiate joint randomized Phase 3 chemotherapy combination trials for NSCLC and triple-negative breast cancer (TNBC) in 2025.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/TIL_sentiment_and_message_volume_Jan_7_premarket_960267c1cd.png" alt="TIL sentiment and message volume Jan 7 premarket.png" width="1318" height="324"><figcaption>TIL sentiment and message volume Jan 7 as of 11:45 am ET | source: Stocktwits</figcaption></figure>Retail investors on Stocktwits reacted positively, pushing sentiment to ‘extremely bullish’ and boosting its message volume.&nbsp;<stembedurl>https://stocktwits.com/Blackcoupe369/message/599159968</stembedurl>Jefferies also noted that the stock is trading at cash value, which, combined with SYN-2510’s potential, suggests substantial growth opportunities.Instil reported $122.9 million in cash reserves as of September 2024, saying it was sufficient to fund its operations through at least 2026.&nbsp;The stock has climbed over 240% in the past year, driven by optimism around its innovative cancer therapies and impending trials, making it a standout player in the small-cap oncology space.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Instil Bio Stock Soars After Jefferies Upgrade On 'Early Mover' Cancer Drug Candidate: Retail Jubilant

Jefferies highlighted SYN-2510 as an “early mover” in the competitive cancer drug space, with significant upside expected from its planned clinical trials.

Equity

Shares of Instil Bio Inc. (TIL) skyrocketed over 60% on Friday, placing it among the top five gainers on U.S. stock exchanges and one of the top 20 trending tickers on Stocktwits, where message volume jumped 340%.The surge came after Baird raised its price target on the stock to $180, implying a 146% upside, while maintaining an ‘Outperform’ rating.Baird’s optimism is growing enthusiasm for Instil’s PD-L1xVEGF bispecific antibody, driven by positive data from peers like Akeso’s ivonescimab and Summit’s BNT327 in the same space.Analysts noted recent results and data released ahead of the European Society for Medical Oncology (ESMO) meeting have increased faith in this drug class for treating cancers like triple-negative breast, RCC, and head and neck.Baird expects continued momentum in this therapeutic area at ESMO, seeing further growth opportunities for Instil Bio. Despite the recent rally, the brokerage believes the stock remains undervalued, suggesting more room for gains.Baird’s price target hike follows H.C. Wainwright’s upgrade a day earlier, when it raised its price target from $25 to $40 with a ‘Buy’ rating. Wainwright expressed increased confidence in Instil’s SYN-2510, highlighting its strong antitumor synergy compared to traditional VEGF blockers and PD-L1 antibodies.Instil also announced a restructuring plan last week, including shutting down operations in Manchester, U.K., and laying off its remaining workforce there. The restructuring will cost up to $5.5 million, including $2.2 million in asset impairments and $2 million in severance.<figure class="image"><a href="https://stocktwits.com/symbol/TIL"><img style="aspect-ratio:1320/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/TIL_sentiment_and_message_volume_Sep_13_0d4fea2fed.png" alt="TIL sentiment and message volume Sep 13.png" width="1320" height="324"></a><figcaption>TIL sentiment and message volume Sep 13</figcaption></figure>Despite bullish analyst notes, retail investors remain wary. Sentiment on Stocktwits is ‘extremely bearish,’ with users questioning the sustainability of the stock’s rapid ascent.“$TIL 13$ last week, now 77$,” noted one user.<stembedurl>https://stocktwits.com/patbourque/message/585998096</stembedurl>Another warned, “$TIL from $9 to $70 in a few days!!! This is not going to go well next week.”<stembedurl>https://stocktwits.com/ProBulish/message/585995548</stembedurl>Adding to concerns, Instil’s fundamentals look shaky. The company reported zero revenue in the latest quarter, only $6.78 million in cash, and holds a $52.1 million mortgage construction loan on its Tarzana, California property, with an option to draw an additional $32.9 million.Instil Bio has soared 624% in the last month, and retail investors are exercising caution for now.Read next: <a href="https://stocktwits.com/news/markets/equity/mstr-stock-rises-on-bitcoin-buy-retail-bullish/c7z62Y5R5B">MicroStrategy Stock Surges On $1B Bitcoin Buy Amid Crypto Dip: Retail Bulls Rejoice</a> &nbsp;

Instil Bio Soars On Baird’s Price Target Boost: Retail Remains On Sidelines Amid Wild Surge

Despite a recent rally in Instil Bio shares, Baird believes the stock remains undervalued, suggesting more room for gains.

Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.

TIL
Instil Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TIL News

TILInstil Bio Inc